Topiramate (Topamax)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Migraine, Epilepsy, Primary Generalized Tonic-Clonic Seizures

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (60)
Epilepsy
NCT02201251 · Janssen Research & Development, LLC
2014-10-06 – 2020-04-30 · Epilepsy
What this study did
NCT00210782 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-06 – 2007-08 · Epilepsy
What this study did
NCT00004776 · National Center for Research Resources (NCRR)
started 1993-11 · Lennox-Gastaut Syndrome
What this study did
NCT00231556 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1999-07 – 2003-09 · Epilepsy, Seizures, Epilepsies, Partial, Epilepsy, Generalized, Epilepsy, Tonic-Clonic
What this study did
NCT00230698 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1995-11 – 2002-08 · Epilepsy, Epilepsies, Partial, Seizures
What this study did
NCT00236717 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1997-09 – 2000-11 · Epilepsy, Seizures
What this study did
NCT00236743 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1994-06 – 2000-10 · Epilepsy, Epilepsies, Partial, Seizures
What this study did
NCT00236886 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1998-05 – 2000-06 · Epilepsy, Epilepsies, Partial, Epilepsy, Generalized, Seizures
What this study did
Migraine
NCT06347497 · Kafrelsheikh University
2024-04-01 – 2026-04-30 · Migraine
What this study did
NCT06243692 · Kafrelsheikh University
2024-02-01 – 2025-02-25 · Migraine Disorders
What this study did
NCT06248931 · Kafrelsheikh University
2022-05-01 – 2024-06-30 · Migraine Disorders
What this study did
NCT01581281 · Children's Hospital Medical Center, Cincinnati
2012-06 – 2016-01 · Migraine, Migraine Disorders, Headache
What this study did
NCT00772031 · Anne Lindblad
2008-10 – 2010-09 · Chronic Migraine
What this study did
NCT00210535 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-06 – 2006-11 · Migraine, Vascular Headaches
What this study did
NCT00216619 · Janssen Pharmaceutica N.V., Belgium
2003-11 – 2006-08 · Migraine
What this study did
NCT00210860 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-09 – 2006-03 · Migraine
What this study did
NCT00210821 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-02 – 2005-11 · Migraine, Headache
What this study did
NCT00210873 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-02 – 2005-08 · Migraine
What this study did
NCT00216606 · Janssen Pharmaceutica N.V., Belgium
2003-12 – 2005-07 · Migraine
What this study did
NCT00210912 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003-09 – 2005-04 · Migraine
What this study did
NCT00237302 · Ortho-McNeil Neurologics, Inc.
2001-07 – 2003-09 · Migraine
What this study did
NCT00236561 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-04 – 2002-12 · Migraine, Common Migraine, Classic Migraine, Headache
What this study did
NCT00231595 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-03 – 2002-11 · Migraine, Common Migraine, Classic Migraine, Headache
What this study did
NCT00253175 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2000-10 – 2001-12 · Vascular Headaches, Migraine
What this study did
Primary Generalized Tonic-Clonic Seizures
NCT00236418 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1994-12 – 1996-12 · Epilepsy, Seizures
What this study did
Other / comorbidity
NCT05209984 · Eurofarma Laboratorios S.A.
2026-04 – 2028-03 · Overweight, Obesity
What this study did
NCT03479086 · South West Sydney Local Health District
2017-06-20 – 2020-11-01 · Alcohol Dependence
What this study did
NCT02273804 · Assistance Publique - Hôpitaux de Paris
2016-06-01 – 2018-01-23 · Obese Children and Adolescents
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT02810483 · Assistance Publique - Hôpitaux de Paris
2012-12 – 2016-06 · Prader-Willi Syndrome
What this study did
NCT00571246 · Yale University
2012-06 – 2016-06 · Alcohol Dependence, Post Traumatic Stress Disorder
What this study did
NCT00755716 · UConn Health
2006-04 – 2013-08 · Tobacco Dependence
What this study did
NCT00448825 · Bankole Johnson
2007-03 – 2013-06 · Alcohol Dependence, Cocaine Dependence
What this study did
NCT00249691 · Bankole Johnson
2005-10 – 2012-10 · Cocaine-Related Disorders
What this study did
NCT00280839 · Lindner Center of HOPE
— · Smoking Cessation
What this study did
NCT00463775 · Elizabeth Ralevski
2007-03 – 2009-05 · Alcohol Dependence, Borderline Personality Disorder
What this study did
NCT00245583 · Icahn School of Medicine at Mount Sinai
2005-10 – 2009-05 · Pathological Gambling
What this study did
NCT00206336 · Baylor College of Medicine
2004-10 – 2008-12 · Tourette Syndrome
What this study did
NCT00206323 · Baylor College of Medicine
2004-09 – 2008-12 · Tourette Syndrome
What this study did
NCT00243984 · Northeastern Ohio Universities College of Medicine
2005-03 – 2007-11 · Metabolic Syndrome X, Diabetes Mellitus, Type 2
What this study did
NCT00187928 · University of Florida
2003-01 – 2006-03 · Obsessive-Compulsive Disorder
What this study did
NCT00307619 · Janssen-Cilag Farmaceutica Ltda.
2003-11 – 2005-04 · Binge Eating
What this study did
NCT00236496 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-10 – 2004-02 · Essential Tremor
What this study did
NCT00237289 · Ortho-McNeil Neurologics, Inc.
2001-10 – 2003-10 · Bipolar Disorder
What this study did
NCT00037674 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-01 – 2003-05 · Bipolar Disorder
What this study did
Phase 2/3 (8)
Migraine
NCT00131443 · Monarch Medical Research
2004-02 – 2006-08 · Basilar Migraine
What this study did
Other / comorbidity
NCT03176953 · VA Office of Research and Development
2017-11-01 – 2023-09-30 · PTSD and Alcohol Use Disorder
What this study did
NCT01182766 · University of Virginia
2011-11-01 – 2017-10-06 · Alcohol Dependence, Nicotine Dependence
What this study did
NCT01811940 · New York State Psychiatric Institute
2013-07 – 2017-06 · Cocaine Dependence
What this study did
NCT00884884 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2007-09 – 2015-10 · Alcohol Dependence
What this study did
NCT01145677 · Chiang Mai University
2010-06 – 2011-06 · Alcohol Dependence
What this study did
NCT00204386 · University of Oklahoma
2002-09 – 2007-05 · Posttraumatic Stress Disorder
What this study did
NCT00210808 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003-09 – 2005-03 · Obesity, Binge-Eating Disorder
What this study did
Phase 2 (49)
Epilepsy
NCT00210574 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-03 – 2006-10 · Epilepsy, Absence
What this study did
NCT00236847 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1989-12 – 1993-07 · Epilepsy, Epilepsies, Partial, Seizures
What this study did
NCT00236873 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1989-10 – 1993-05 · Epilepsy, Epilepsies, Partial, Seizures
What this study did
NCT00236860 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1989-05 – 1992-02 · Epilepsy, Epilepsies, Partial, Seizures
What this study did
NCT00236730 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1988-06 – 1990-12 · Epilepsy, Epilepsies, Partial, Seizures
What this study did
NCT00236691 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1988-07 – 1990-12 · Epilepsy, Epilepsies, Partial, Seizures
What this study did
Migraine
NCT05403229 · Chang Gung Memorial Hospital
2022-10-17 – 2025-09 · Sudden Deafness, Sudden Sensorineural Hearing Loss
What this study did
NCT03280342 · University of Minnesota
2017-10-30 – 2018-09-13 · Migraine, Headache
What this study did
NCT01799590 · Janssen Pharmaceutical K.K.
2007-08 – 2009-11 · Migraine
What this study did
NCT01081795 · Janssen Pharmaceutical K.K.
2007-04 – 2009-01 · Migraine
What this study did
NCT00158002 · Monarch Medical Research
2004-02 – 2006-08 · Basilar Migraine
What this study did
NCT00261469 · Janssen-Ortho Inc., Canada
2003-04 – 2004-11 · Headache
What this study did
Other / comorbidity
NCT03667846 · NYU Langone Health
2019-10-10 – 2025-08-31 · Post Traumatic Stress Disorder, Alcohol Use Disorder
What this study did
NCT04007393 · University of Minnesota
2019-11-21 – 2025-03-11 · Adolescent Obesity
What this study did
NCT04621929 · University of Florida
2021-03-31 – 2024-11-14 · Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese, Pre-Diabetes
What this study did
NCT01950520 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2014-02-07 – 2024-06-11 · Healthy Volunteers
What this study did
NCT04572217 · Janey Pratt
2022-06-01 – 2022-06-01 · Pediatric Obesity
What this study did
NCT04095104 · University of Colorado, Denver
2020-01-15 – 2022-01-25 · Obesity, Morbid, Bariatric Surgery, Adolescent, Young Adult, Drug Therapy
What this study did
NCT02878798 · Virginia Commonwealth University
2018-02-12 – 2021-09-28 · Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
What this study did
NCT02371889 · University of Pennsylvania
2014-12-18 – 2020-02 · Alcoholism, Alcohol Use Disorder (AUD)
What this study did
NCT01859013 · University of Minnesota
2013-06 – 2017-04 · Obesity, Morbid, Obesity, Weight Loss
What this study did
NCT02074904 · University of Pennsylvania
2015-05 – 2017-03 · Alcohol Drinking
What this study did
NCT01789047 · Rush University Medical Center
2013-03 – 2016-07 · Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
What this study did
NCT02138058 · University of Sao Paulo
2015-01 – 2016-06 · Compulsive Shopping
What this study did
NCT00370188 · Centre for Addiction and Mental Health
started 2006-09 · Gambling
What this study did
NCT00802412 · VA Office of Research and Development
2009-01 – 2015-06 · Nicotine Dependence, Alcohol Dependence
What this study did
NCT01351753 · University of Iowa
2011-03 – 2014-01-09 · Obesity, Metabolic Syndrome X
What this study did
NCT01764685 · University of Pennsylvania
2013-01 – 2014-01 · Heavy Drinking, HIV, Alcohol Dependence
What this study did
NCT00006205 · Bankole Johnson
2005-03 – 2013-12 · Alcoholism
What this study did
NCT01241019 · Meyer Children's Hospital IRCCS
2010-02 – 2013-12 · Hypoxic Ischemic Encephalopathy
What this study did
NCT01110434 · Brown University
2009-12 – 2012-05 · Cannabis Abuse, Cannabis Dependence
What this study did
NCT00685178 · Johns Hopkins University
2007-02 – 2011-09 · Cocaine Dependence
What this study did
NCT00223626 · Bankole Johnson
2007-01 – 2010-12 · Cocaine-Related Disorders
What this study did
NCT01843699 · University of Sao Paulo
2009-06 – 2010-11 · Pathological Gambling
What this study did
NCT00167245 · Kyle Kampman
2004-09 – 2010-06 · Alcoholism, Cocaine Dependence
What this study did
NCT00421603 · New York State Psychiatric Institute
2007-02 – 2010-05 · Cocaine Dependence
What this study did
NCT00345371 · National Institute on Drug Abuse (NIDA)
2006-04 – 2008-12 · Methamphetamine
What this study did
NCT00223639 · Bankole Johnson
2005-09 – 2008-07 · Alcoholism
What this study did
NCT00300742 · University of Virginia
2006-03 – 2008-07 · Alcohol Dependence, Binge Eating
What this study did
NCT00217295 · Multiple Sclerosis Institute
2004-04 – 2007-12 · Multiple Sclerosis
What this study did
NCT00296959 · University Health Network, Toronto
2004-09 – 2007-03 · Parkinson's Disease
What this study did
NCT00208858 · Emory University
2004-12 – 2006-12 · Tobacco Use Disorder
What this study did
NCT00210925 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-03 – 2006-08 · Alcoholism
What this study did
NCT00011804 · National Institute of Dental and Craniofacial Research (NIDCR)
2001-02 – 2005-02 · Sciatica
What this study did
NCT00231647 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-02 – 2004-10 · Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
What this study did
NCT00231673 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-07 – 2003-01 · Diabetic Neuropathies, Diabetes Mellitus, Type 2, Polyneuropathies
What this study did
NCT00236626 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2000-04 – 2002-05 · Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
What this study did
NCT00231608 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1998-12 – 2002-01 · Obesity
What this study did
NCT00236613 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2000-09 – 2001-07 · Obesity
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT06282783 · Erasmus Medical Center
2024-09 – 2025-08 · HIV-1-infection, Hiv, HIV Infections, HIV I Infection
What this study did
NCT01765218 · Kristin R Hoffman
2013-02 – 2022-01-27 · Hypoxic Ischemic Encephalopathy
What this study did
NCT01641445 · Brown University
2012-07 – 2017-04-12 · Alcohol Drinking
What this study did
Phase 1 (25)
Epilepsy
NCT02707965 · Food and Drug Administration (FDA)
2017-06-08 – 2018-09-04 · Epilepsy
What this study did
NCT01439438 · GlaxoSmithKline
2011-07-22 – 2011-09-11 · Epilepsy, Tonic-Clonic
What this study did
NCT01114854 · Supernus Pharmaceuticals, Inc.
2010-06 – 2011-01 · Epilepsy
What this study did
NCT00598923 · University of Pennsylvania
2004-11 – 2009-02 · Traumatic Brain Injury, Epilepsy
What this study did
NCT00233012 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-06 – 2007-10 · Seizures
What this study did
NCT02283814 · Bial - Portela C S.A.
2007-01 – 2007-02 · Epilepsy
What this study did
NCT00701493 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-11 – 2004-12 · Epilepsy
What this study did
Migraine
NCT03335163 · University of Colorado, Denver
2018-03-15 – 2021-04-22 · Migraine, Migraine;Menstrual, Contraception
What this study did
NCT04401137 · SK Chemicals Co., Ltd.
2020-07-01 – 2020-10-06 · Migraine
What this study did
NCT00753493 · University of Minnesota
2008-08 – 2010-08 · Epilepsy, Migraines
What this study did
NCT00752466 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003-03 – 2004-03 · Human Volunteers, Migraine
What this study did
Other / comorbidity
NCT04613024 · Stanford University
2025-07-01 – 2027-07-01 · Weight Loss, Pain, Postoperative
What this study did
NCT04986631 · University of Minnesota
2022-04-04 – 2024-09-26 · Obesity, Childhood
What this study did
NCT02239913 · University of Kentucky
2014-09 – 2019-09 · Cocaine Use Disorder
What this study did
NCT03120468 · Nassima Ait-Daoud Tiouririne
2017-05-01 – 2019-06-30 · Alcoholism
What this study did
NCT00606411 · Massachusetts General Hospital
2008-01 – 2018-11-29 · Sleep-Related Eating Disorder
What this study did
NCT03308669 · Eli Lilly and Company
2017-10-16 – 2017-12-02 · Healthy
What this study did
NCT01426542 · University of California, Davis
2011-03 – 2017-07-28 · Cyanotic Congenital Heart Disease
What this study did
NCT00939705 · Torrent Pharmaceuticals Limited
— · Healthy
What this study did
NCT02884050 · University of Florida
2009-04 – 2011-01 · Alteration of Cognitive Function
What this study did
NCT00769158 · Bankole Johnson
2008-10 – 2010-12 · Alcoholism
What this study did
NCT00518466 · VIVUS LLC
2007-07 – 2007-12 · Obesity
What this study did
NCT00939692 · Torrent Pharmaceuticals Limited
2007-01 – 2007-04 · Healthy
What this study did
NCT00986336 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-02 – 2002-11 · Bipolar Disorder
What this study did
NCT00986128 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2001-03 – 2002-10 · Bipolar Disorder
What this study did
Phase 4 (50)
Epilepsy
NCT03307863 · University of Sao Paulo
2017-11-01 – 2028-11-30 · Contraception, Drug Interactions
What this study did
NCT04759196 · Université de Sherbrooke
2021-03-01 – 2024-12 · Chronic Subdural Hematoma, Epilepsy; Seizure, Cortical Depression; Cortical Depolarization, Nonepileptic, Stereotypical and Intermittent Symptoms, NESIS
What this study did
NCT03689114 · Mario Negri Institute for Pharmacological Research
2021-05-10 – 2024-06-30 · Epilepsies, Partial
What this study did
NCT01627860 · Johnson & Johnson Taiwan Ltd
2010-02 – 2011-01 · Epilepsy
What this study did
NCT01689649 · Janssen Research & Development, LLC
2008-05-02 – 2010-01-19 · Epilepsy
What this study did
NCT00855738 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-05 – 2009-06 · Focal Epilepsy
What this study did
NCT00266604 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-12 – 2007-06 · Epilepsy, Seizures, Epilepsies, Partial, Epilepsy, Generalized, Seizures, Tonic-Clonic
What this study did
NCT00216567 · Janssen Korea, Ltd., Korea
2002-12 – 2006-02 · Epilepsy, Rolandic
What this study did
Migraine
NCT06799169 · University of California, Irvine
2025-06-01 – 2030-12 · Tinnitus
What this study did
NCT06972056 · Mayo Clinic
2025-07-09 – 2029-12-01 · Migraine
What this study did
NCT05582837 · University of California, Irvine
2022-08-01 – 2027-12-30 · Ménière
What this study did
NCT06089356 · Tanta University
2023-01-01 – 2024-01-01 · Migraine
What this study did
NCT04404439 · University of California, Irvine
2019-09-26 – 2023-12-30 · Tinnitus, Subjective, Tinnitus
What this study did
NCT05759845 · Dr. Reaz Mahmud
2022-08-22 – 2023-05-31 · Migraine
What this study did
NCT02191579 · Allergan
2014-08-05 – 2017-09-01 · Migraine Disorders
What this study did
NCT01700387 · Cady, Roger, M.D.
2012-10 – 2014-08 · Chronic Migraine
What this study did
NCT00846495 · Clinvest
2009-08 – 2011-01 · Migraine
What this study did
NCT02424318 · SMG-SNU Boramae Medical Center
2008-12 – 2010-12 · Migraine Disorders
What this study did
NCT01060111 · Janssen Korea, Ltd., Korea
2006-07 – 2008-07 · Migraine
What this study did
NCT00212810 · Ortho-McNeil Neurologics, Inc.
2005-09 – 2007-08 · Migraine, Headache, Classic Migraine, Common Migraine
What this study did
NCT00210496 · Janssen-Ortho LLC
2005-06 – 2007-06 · Migraine, Classic Migraine, Common Migraine
What this study did
Other / comorbidity
NCT05663749 · All India Institute of Medical Sciences, Bhubaneswar
2022-09-20 – 2023-08-20 · Metabolic Syndrome, Schizophrenia
What this study did
NCT03018704 · VA Office of Research and Development
2017-08-01 – 2021-12-31 · Alcohol Use Disorder
What this study did
NCT04453306 · Hospital de Clinicas de Porto Alegre
2014-05 – 2021-12 · Obesity, Polycystic Ovary Syndrome, Hyperandrogenism
What this study did
NCT04523935 · Sathbhavana Brain Clinic
2005-12-07 – 2020-08-04 · Cerebral Palsy, Excessive Crying, Pain
What this study did
NCT01749215 · University of California, San Francisco
2013-02 – 2019-07 · Alcohol Dependence, Posttraumatic Stress Disorder (PTSD)
What this study did
NCT00182520 · McMaster University
2002-01 – 2019-01 · Obsessive Compulsive Disorder
What this study did
NCT00182455 · McMaster University
2004-03-01 – 2018-12-01 · Social Phobia
What this study did
NCT01889602 · University of Minnesota
2013-07 – 2016-08 · Cognitive Deficits
What this study did
NCT01750268 · University of California, San Francisco
2012-11 – 2015-10 · Traumatic Brain Injury (TBI), Hazardous and Harmful Alcohol Use
What this study did
NCT00572117 · Stanford University
2007-08 – 2014-07 · Bipolar Disorder, Alcoholism, Alcohol Dependence
What this study did
NCT00393978 · University of Cincinnati
2006-11 – 2014-03 · Bipolar Disorder, Cannabis-Related Disorder
What this study did
NCT01087736 · University of California, San Francisco
2010-04 – 2013-12 · PTSD, Alcohol Abuse, Alcoholism
What this study did
NCT00626925 · UConn Health
2008-02 – 2013-11 · Alcohol Drinking
What this study did
NCT00862095 · Madigan Army Medical Center
2008-06 – 2013-04 · Headache
What this study did
NCT01135602 · Chiang Mai University
2010-07 – 2012-03 · Alcohol Dependence
What this study did
NCT00988481 · Neuropsychiatric Research Institute, Fargo, North Dakota
2009-09 – 2010-09 · Bulimia Nervosa
What this study did
NCT00550394 · University of Cincinnati
2008-04 – 2010-06 · Bipolar Disorder, Alcohol Abuse
What this study did
NCT00725920 · Federal University of São Paulo
2007-01 – 2009-12 · Posttraumatic Stress Disorder
What this study did
NCT00394095 · University of Cincinnati
2006-12 – 2009-09 · Bipolar Disorder, Weight Gain
What this study did
NCT00329407 · Boston University
2003-09 – 2008-06 · Alcoholism
What this study did
NCT00153699 · Chinese University of Hong Kong
2004-09 – 2007-07 · Glaucoma, Angle-Closure
What this study did
NCT00286988 · Monarch Medical Research
2006-03 – 2007-06 · Vomiting
What this study did
NCT00432549 · The New England Center for Headache, P.C.
2007-01 – 2007-02 · Analgesic Rebound Headache
What this study did
NCT00211744 · Montefiore Medical Center
2004-08 – 2006-08 · Obsessive-compulsive Disorder
What this study did
NCT00203190 · Thomas Jefferson University
2004-09 – 2006-06 · Cluster Headache
What this study did
NCT00200941 · Neurocare
2001-08 – 2005-04 · Restless Legs Syndrome
What this study did
NCT00203463 · Tuscaloosa Research & Education Advancement Corporation
2001-07 – 2004-09 · PTSD
What this study did
NCT00208130 · Creighton University
2001-10 – 2004-03 · Post-Traumatic Stress Disorder
What this study did
NCT02040311 · University of Copenhagen
2000-08 – 2002-06 · Obesity
What this study did
Early phase / not applicable (20)
Epilepsy
NCT02113787 · Seoul National University Hospital
2014-02 – 2017-05 · Epilepsy
What this study did
Migraine
NCT02169830 · St. Louis University
2014-08-22 – 2019-10-30 · Migraine Disorders
What this study did
NCT03712917 · Ataturk University
2019-03-01 – 2019-03-31 · Migraine
What this study did
NCT03767062 · Ataturk University
2019-03-01 – 2019-03-31 · Medication Overuse Headache, Chronic Migraine, Headache
What this study did
NCT02643719 · NYU Langone Health
2015-12 – 2017-10 · Migraine
What this study did
NCT01161017 · Rambam Health Care Campus
2008-07 – 2014-05 · Migraine
What this study did
NCT00732108 · University of California, San Francisco
2008-11 – 2011-08 · Migraine, Headache, Dizziness
What this study did
NCT00777218 · University of South Alabama
2007-08 – 2011-07 · Migraine
What this study did
Other / comorbidity
NCT02808533 · Centre for Addiction and Mental Health
2016-05 – 2026-08 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT04154813 · Shanghai Mental Health Center
2020-02-01 – 2022-11-30 · Fluoxetine
What this study did
NCT01970566 · US Department of Veterans Affairs
2013-11 – 2017-11 · Obesity, Diabetes Mellitus
What this study did
NCT01408641 · University of Maryland, Baltimore
2012-09 – 2013-08 · Alcohol Dependence, Alcoholism, Alcohol Abuse, Alcohol Use Disorder, PTSD, Posttraumatic Stress Disorder
What this study did
NCT01384279 · Beitou Armed Forces Hospital, Taipei, Taiwan
2011-05 – 2012-01 · Obesity
What this study did
NCT00396734 · Hadassah Medical Organization
2007-04 – 2011-04 · Opioid-Related Disorders, Cocaine-Related Disorders
What this study did
NCT00794313 · Oregon Health and Science University
2009-09 – 2010-06 · Parkinson's Disease
What this study did
NCT00768677 · The Zucker Hillside Hospital
started 2003-07 · Eating Disorders, Bulimia Nervosa
What this study did
NCT00065923 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2002-07 – 2005-12 · Prader-Willi Syndrome, Self-Injurious Behavior
What this study did
NCT00004807 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
started 1995-01 · Rett Syndrome
What this study did
NCT00902473 · Ranbaxy Laboratories Limited
2001-09 – 2001-10 · Healthy
What this study did
NCT00901784 · Ranbaxy Laboratories Limited
2001-09 – 2001-10 · Healthy
What this study did
Used as active comparator (21)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Phase 2/3 (1)
Other / comorbidity
NCT05958160 · Lady Hardinge Medical College
2023-07-20 – 2024-10-31 · Epileptic Spasms, Failed Hormonal Therapy
What this study did
Phase 2 (1)
Other / comorbidity
NCT00862563 · Boston Medical Center
2009-05 – 2013-08 · Alcoholism, Alcohol Dependence, Alcohol Abuse
What this study did
Phase 1 (9)
Migraine
NCT02645370 · Xijing Hospital
2016-02 – 2017-07 · Migraine
What this study did
Other / comorbidity
NCT00649467 · Mylan Pharmaceuticals Inc
2005-11 – 2005-12 · Healthy
What this study did
NCT00648934 · Mylan Pharmaceuticals Inc
2005-11 – 2005-12 · Healthy
What this study did
NCT00649740 · Mylan Pharmaceuticals Inc
2005-11 – 2005-12 · Healthy
What this study did
NCT00905346 · Teva Pharmaceuticals USA
2002-06 – 2002-07 · Healthy
What this study did
NCT00904943 · Teva Pharmaceuticals USA
2002-06 – 2002-07 · Healthy
What this study did
NCT00905164 · Teva Pharmaceuticals USA
2002-06 – 2002-06 · Healthy
What this study did
NCT00905567 · Teva Pharmaceuticals USA
2001-06 – 2001-06 · Healthy
What this study did
NCT00905606 · Teva Pharmaceuticals USA
2001-06 – 2001-06 · Healthy
What this study did
Phase 4 (5)
Epilepsy
NCT01229735 · UCB Korea Co., Ltd.
2010-11 – 2015-05 · Epilepsy
What this study did
NCT00154076 · Eisai Korea Inc.
2005-09 – 2008-12 · Epilepsy
What this study did
Migraine
NCT07655440 · Stanford University
2026-07 – 2031-07 · Migraine Associated Vertigo, Tinnitus, Migraine, Vestibular Migraine
What this study did
NCT03828539 · Novartis Pharmaceuticals
2019-02-22 – 2020-07-29 · Migraine
What this study did
NCT02639598 · Taipei Veterans General Hospital, Taiwan
2012-06 – 2015-03 · Chronic Migraine
What this study did
Early phase / not applicable (2)
Migraine
NCT05516251 · Tongji Hospital
2021-10-01 – 2023-09-30 · Migraine, Classic
What this study did
NCT01096420 · Kuang Tien General Hospital
2008-08 – 2010-08 · Patients With Chronic Migraine
What this study did
Studied as part of a combination product (16)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (2)
Other / comorbidity
NCT03374956 · Mayo Clinic
2017-12-11 – 2022-05-26 · Obesity
What this study did
NCT02635386 · Woman's
2016-03-22 – 2020-10-09 · Polycystic Ovary Syndrome, Obesity
What this study did
Phase 2 (6)
Other / comorbidity
NCT07790913 · St. Jude Children's Research Hospital
2026-12 – 2031-08 · Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
What this study did
NCT06299891 · Seattle Children's Hospital
2025-03-01 – 2026-11-30 · Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
What this study did
NCT04298203 · University of Minnesota
2021-08-04 – 2026-05-22 · Obesity
What this study did
NCT04721873 · University of California, San Diego
2020-12-18 – 2024-06-30 · Colitis, Ulcerative, Obesity
What this study did
NCT02301416 · Wake Forest University Health Sciences
2014-12 – 2018-06-27 · Obesity, Metabolic Surgery, Weight Loss, Bariatric Surgery Procedures
What this study did
NCT00600067 · VIVUS LLC
2008-01 – 2008-11 · Diabetes
What this study did
Phase 1 (2)
Other / comorbidity
NCT04881799 · University of Minnesota
2022-07-07 – 2026-10-27 · Pediatric Obesity
What this study did
NCT02553824 · Stanford University
2015-10-30 – 2017-04-15 · Binge Eating Disorder, Bulimia Nervosa
What this study did
Phase 4 (6)
Other / comorbidity
NCT07213466 · Mayo Clinic
2026-01-19 – 2029-02-01 · Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
What this study did
NCT06854614 · The Cleveland Clinic
2025-03-01 – 2028-04-28 · Obesity
What this study did
NCT05579249 · Novo Nordisk A/S
2023-01-19 – 2024-11-27 · Obesity
What this study did
NCT04531176 · The Cleveland Clinic
2020-09-01 – 2023-08-04 · Type 2 Diabetes, Obesity
What this study did
NCT04408586 · Mayo Clinic
2020-06-03 – 2022-10-11 · Obesity
What this study did
NCT01834404 · Mayo Clinic
2013-04 – 2014-03 · Obesity
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Other / comorbidity
NCT03603080 · Hartford Hospital
2019-03-01 – 2022-09-01 · Obesity
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07707544 · Sohag University
2026-06-01 – 2026-12-01 · Idiopathic Intracranial Hypertension
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Topiramate (Topamax): this drugApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
CB03-154Phase 2Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
Huperzine A (SPN-817)Phase 2Small moleculeAcetylcholinesteraseWeak signal
NCT03156439: Participants were given the experimental treatment twice a day, with the dose increased every two to three days until a maximum daily dose of 2.5 mg was reached. Participants tolerated the treatment well, with mild to moderate, transient and non-dose-limiting adverse events.

Large race: only the 64 furthest-along competitors are listed; 9 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Topiramate (Topamax) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 4MigraineRecruiting
Est. primary completion 2027-12-30 · NCT05582837 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 4MigraineRecruiting
Est. primary completion 2029-03-01 · NCT06972056 · CT.gov ↗
What to watch

See the full readout calendar ↗